Company intelligence / Profile preview

SyzOnc

Philadelphia, Pennsylvania, United Statessyzonc.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

SyzOnc is developing next-generation cancer therapies by leveraging a proprietary AI-driven systems biology platform to map and modulate the 3D solid tumor ecosystem. Their approach identifies multi-modal protein targets within the tumor microenvironment—simultaneously affecting cancer cells, immune cells, and matrix components—to discover novel small molecule modulators. The company’s technology aims to improve drug candidate selection and clinical outcomes for patients with limited treatment options. Current efforts are focused on preclinical validation using sarcoma models; no clinical results have been reported yet.

Therapeutic areas: Oncology
Modalities: Small moleculesModulators targeting the tumor microenvironment
Industry: Biotech

Beyond the preview

Go deeper on SyzOnc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SyzOnc.

Explore the full profile